Valibose

• CAT Number: I009979
• CAS Number: 83470-79-5
• Molecular Formula: C10H21NO6
• Molecular Weight: 251.279
• Purity: ≥95%
• Synonyms: Valibose;(1R,2S,3S,4S,6R)-4-((1,3-dihydroxypropan-2-yl)amino)-6-(hydroxymethyl)cyclohexane-1,2,3-triol
• Target: Glucosidase
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• InChI: InChI=1S/C10H21NO6/c12-2-5-1-7(11-6(3-13)4-14)9(16)10(17)8(5)15/h5-17H,1-4H2/t5-,7+,8-,9+,10+/m1/s1
• InChIKey: LWJUMCBIHCZWBT-JTBFQXKRSA-N
• SMILES: O[C@H]1[C@@H](NC(CO)CO)C[C@H](CO)[C@@H](O)[C@@H]1O

Valibose An α-glucosidase inhibitor potentially for the treatment of diabetes. Valibose significantly decreased postprandial and fasting blood glucose, urine glucose, and reduced the levels of serum fructosamine. Valibose also decreased plasma triglyceride and cholesterol levels. Valibose ameliorated metabolic disturbance of glucose and lipids. In addition, valibose markedly reduced level of serum NAG and BUN, and decreased the weight index of kidney.

Reference

1:Yao Xue Xue Bao. 2013 Aug;48(8):1227-32. [Valibose, an alpha-glucosidase inhibitor, ameliorates the metabolic disorder of glucose and lipids and the nephropathy in streptozotocin-induced diabetic rats].Liu Q,Liu SN,Sun SJ,Shen ZF, PMID: 24187828 Abstract: This study is to evaluate the anti-diabetic effects of the alpha-glucosidase inhibitor valibose in a streptozotocin (STZ)-induced type 1 diabetes rat model. Diabetes was induced by a single dose of STZ (58 mg x kg(-1), ip) in SD rats, rats with elevated fasting blood glucose levels (250-450 mg x dL(-1)) were selected and divided into five groups (n = 10 in each). Another ten normal SD rats were chosen as normal group. Valibose mixed with the high sucrose diets (0.4, 1.0 and 2.5 mg 100 g(-1) diets) or acarbose (30 mg x 100 g(-1) diets) was administrated in the diabetic rats for about 5 weeks. In all groups, fasting and postprandial plasma glucose, plasma lipids, glycosylated serum protein, N-acetyl-beta-D-glucosaminidase (NAG), creatinine (Cre), blood urea nitrogen (BUN) and urine sugar levels were determined during the treatment. At the end of the experiment, the morphological alterations in kidney were evaluated by hematoxylin-eosin (HE) staining. After 3-weeks administration, valibose significantly decreased postprandial and fasting blood glucose, urine glucose, and reduced the levels of serum fructosamine. Valibose also decreased plasma triglyceride and cholesterol levels after 4 weeks treatment. These results indicated that valibose ameliorated metabolic disturbance of glucose and lipids in STZ-induced diabetic rats. In addition, valibose markedly reduced level of serum NAG and BUN, and decreased the weight index of kidney. HE staining showed reduced kidney pathological changes after valibose treatment. The findings of the present study indicate that valibose may be a novel alpha-glucosidase inhibitor for the prevention from hyperglycemia in STZ-induced type 1 diabetes rats. And valibose might have a potential role for protecting against diabetic nephropathy during hyperglycemia.